



Driscoll Health Plan

News and Updates



Date:

May-13

2026

Contact Information

For questions or additional assistance, contact:

Provider Relations
956-632-8308

To enter authorization requests and upload clinical via the Provider Portal, visit driscollhealthplan.com/providers

To verify authorization requirements via the Authorization Requirement Portal, visit driscollhealthplan.com/priorauthcheck

To submit authorization requests or clinical to the UM Dept. via fax, send to 1-866-741-5650

Attention: Authorization Requirement Updates (page 1 of 2)

Effective 06/01/2026, DHP **will** require prior authorization for the following procedure codes:

Pharmacy Services

- J3404- Papzimeos (zopapogene imadenovec-drba), treatment of members 18 years and older with recurrent respiratory papillomatosis with diagnosis: D14.1.
- J9161- Lymphir (denileukin diftitox-cxdl), treatment of members 18 years and older with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy with one of the following diagnoses: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C84.AA.
- J9183- Gemcitabine intravesical system, treatment of bladder cancer in members 18 years and older.
- J9248- melphalan (hepzato), chemotherapy used to target metastatic uveal melanoma in members 18 years and older with one of the following diagnoses: C69.30, C69.31, C69.32, C69.40, C69.41, C69.42.
- Q5134- natalizumab-sztn (tyruko), treatment of members 18 years and older with relapsing forms of multiple sclerosis and moderate to severe Crohn's disease with one of the following diagnosis: G35.A, G35.C0, G35.C1, G35.D, K50.00, K50.012, K50.013, K50.014, K50.018, K50.10, K50.111, K50.112, K50.113, K50.114, K50.118, K50.812, K50.80, K50.811, K51.813, K50.814, K50.818, K50.90, K50.911, K50.912, K50.913, K50.914, K50.918, K50.919.
- C9818- Suzetrigine, non-opioid, oral analgesic approved for moderate-to-severe acute pain in members 18 years and older.
- Q5148- filgrastim-txid (nypozi), filgrastim biosimilar, granulocyte colony stimulating factor (GCSF) used to stimulate the growth of neutrophils.

Wound Care- Skin Substitutes

- G0681- non-sheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less of wound surface area.
- G0682- non-sheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof.
- G0683- non-sheet form skin substitute for a wound surface greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children.
- G0684- non-sheet form skin substitute for a wound surface greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area or part thereof, or each additional 1% of body area of infants and children, or part thereof.

* To access the DHP provider portal, visit driscollhealthplan.com



Date:

May-13

2026

Contact Information

For questions or additional assistance, contact:

Provider Relations
956-632-8308

To enter authorization requests and upload clinical via the Provider Portal, visit driscollhealthplan.com/providers

To verify authorization requirements via the Authorization Requirement Portal, visit driscollhealthplan.com/priorauthcheck

To submit authorization requests or clinical to the UM Dept. via fax, send to 1-866-741-5650

Attention: Authorization Requirement Updates (page 2 of 2)

Effective 06/01/2026, DHP **will** require prior authorization for the following procedure codes:

Genetic Testing

- 81415- Whole Exome Sequencing (WES) analysis, a high-complexity molecular procedure used to detect genetic variants in protein-coding regions of the genome; once per lifetime, members birth through 20 years of age.
- 81416- represents a "trio" or family-based Whole Exome Sequencing (WES) component, used for analyzing comparators (parents/siblings) to diagnose genetic disorders; twice per lifetime, members birth through 20 years of age..
- 81417- re-evaluation of a previously obtained exome sequence to identify genetic causes of unexplained, heritable disorders; once per lifetime.
- 0037U- FoundationOne CDx test identifies alterations in 324 genes and genomic signatures that are isolated from solid tissue samples.
- 0239U- FoundationOne liquid CDx test targeting genomic panel analyzing cell-free DNA from blood for 311 or more genes to identify alterations in solid tumors.
- 81595- mRNA gene expression profiling of 20 genes in heart transplant patients to produce a rejection risk score.
- 0493U- Prospera test, uses next-generation sequencing to quantify the percentage of donor-derived cell-free DNA (dd-cfDNA) in the plasma of transplant recipients to monitor organ transplant health.
- 0540U- a molecular test that measures donor-derived cell-free DNA (dd-cfDNA) in plasma, used to assess the probability of organ transplant rejection.
- 0364U- clonoSEQ® Assay by Adaptive Biotechnologies, used to detect minimal residual disease (MRD) in hematolymphoid cancers, uses NGS on blood or bone marrow to track specific DNA sequences, assisting clinicians in measuring disease burden; for members with one of the following diagnoses: C90.00, C90.01, C90.02, C91.00, C91.01, C91.02, C91.10, C91.11, C91.12.
- 81517- non-invasive serum test that measures three biomarkers—hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1) to assess liver fibrosis risk, in members with one of the following diagnoses: K70.0, K70.10, K70.11, K70.2, K70.30, K70.31, K70.40, K70.41, K70.9, K71.0, K71.10, K71.11, K71.2, K71.3, K71.4, K71.50, K71.51, K71.6, K71.7, K71.8, K71.9, K72.00, K72.01, K72.11, K72.90, K72.91, K73.0, K73.1, K73.2, K73.8, K73.9, K74.00, K74.01, K74.02, K74.10, K74.2, K74.3, K74.4, K74.5, K74.60, K74.69, K75.0, K75.1, K75.2, K75.3, K75.4, K75.81, K75.89, K75.9, K76.0, K76.1, K76.2, K76.3, K76.4, K76.5, K76.6, K76.7, K76.81, K76.82, K76.89, K76.9, K77.
- 81518- molecular test analyzing 11 genes from breast tumor tissue to assess the risk of distant recurrence and determine the likelihood of benefit from extended endocrine therapy in early-stage, ER+ breast cancer patients, for members with one of the following diagnoses: C50.011, C50.012, C50.111, C50.211, C50.212, C50.311, C50.312, C50.411, C50.412, C50.511, C50.512, C50.611, C50.612, C50.811, C50.812, C50.911, C50.912, C50.A0, D05.01, D05.02, D05.11, D05.12, D05.81, D05.82, Z17.0, Z17.21, Z17.31, Z17.32, Z17.410, Z17.411.

* To access the DHP provider portal , visit driscollhealthplan.com